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OUTCOME OF ALLOGENEIC (ALLO) STEM CELL TRANSPLANT (SCT)
AFTER FAILURE OF A PRIOR SCT: A SINGLE CENTER’S EXPERIENCE
Alluri, K.C., Paba, C.E., Nath, R.Methodist University Hospital/Univer-
sity of Tennessee Cancer Institute, Memphis, TN
Introduction: SCT is a curative option for patients with hemato-
logical malignancies.Treatment options for patients who relapse
after a prior SCT are limited and often not curative. There is little
experience of allo-SCT in this setting because of concerns of trans-
plant related mortality.
Methodology: Retrospective review was performed of all pa-
tients who received an allo-SCT at Methodist University Hospital
between february 2003 and february 2008 after failing a prior SCT.
There were 12 (7 males, 5 females) patients. The median age was
45.5 range (25–75) years at the time of allo-SCT. Primary diagnosis
included lymphoma -5 (4 non-hodgkin,1 hodgkin), acute leukemia
-3 and multiple myeloma (MM) - 4. Median number of prior ther-
apies was 4 range (2–7). Prior SCT was autologous (auto) in 10 pa-
tients (1 patient-3 autoSCT; 1 patient-2 autoSCT) and allogeneic
in 2. Eight patients had active disease and 4 were in complete remis-
sion (CR) prior to their allo-SCT. Four patients (all with MM) had
developed a secondary MDS/AML prior to their allo-SCT. SCT
co-morbidity index was $ 3 in 8 and #2 in 4 patients. Median
time from a previous SCT to allo-SCT was 11.6 range (8.6–75.3)
months. Donor was a matched sibling for 8 and unrelated donor
for 4 patients. Preparative regimen was Fludarabine(F) /Melphalan
(140mg/m2) 6 antithymocyte globulin (ATG) 6 Rituxan (R) in 8,
F/cytoxan 6 ATG6 R in 3 and Melphalan (200mg/m2) in one pa-
tient. Graft versus host disease prophylaxis was tacrolimus/metho-
trexate in 10 patients and cyclosporine/ mycophenolate mofetil in 2
patients. All 11 evaluable patients engrafted with a median time to
neutrophil engraftment of 11 range (10–16) days and a median time
to platelet engraftment of 19 range (9–37) days. Nine patients
achieved a CR and 2 had persistent disease after the allo-SCT.
Seven patients died at a median of 151 range (7–524) days post
allo SCT: 5 from tranplant related mortality (TRM) and 2 from
progressive disease. Five patients are alive and disease free at
9,16, 25,42 and 66 months post allo-SCT. Two patients are off
all immunosuppressive therapy.
Conclusion: Allo-SCT after failure of a prior SCT is feasible and
can result in prolonged survival.317
STABLE MIXED DONOR-DONOR CHIMERISM AFTER DOUBLE CORD
BLOOD TRANSPLANTATION
Gertow, J., Berglund, S., Okas, M., Ringden, O., Uhlin, M., Mattsson, J.
Karolinska University Hospital, Huddinge, Stockholm, Sweden
Umbilical cord blood is increasingly used as a source of stem cells
in allogeneic stem cell transplantation due to it’s naı¨ve cell content
and high permissiveness for HLA-mismatch. To overcome problems
of limited cell numbers, double cord blood transplantation (DCBT)
has proven both safe and efficacious. Concerning chimerism analysis
after DCBT, previous studies have indicated single unit predomi-
nance early after DCBT. In the present study we evaluated the chi-
meric pattern in T-, B- and myeloid cells using PCR based
chimerism analysis in patients after DCBT. Of the seven patients
included in this study, five had acute leukemia and two patients
had lymphoma. Five patients received myeloablative conditioning
and two patients were given reduced intensity conditioning. Interest-
ingly, three patients showed mixed donor chimerism in all cell line-
ages at 100 days post-transplantation, and two of them still at 25 and
29 months after DCBT, respectively. These two patients are doing
clinically well, with no infectious complications or signs of relapse,
and neither of them developed acute GVHD after DCBT. All
patients received high dose antithymocyte globulin (ATG) before
DCBT, which could be an explanation for an increased tolerance
between the cord blood units. Immunological studies revealed phe-
notypic differences between the two cord blood units. Among other
things, antigen presenting cells and T cells of memory phenotype
predominated in one cord blood unit, whereas natural killer cells
were found in higher frequencies in the other unit. In conclusion,
in this study donor-donor mixed chimerism was common after
high dose ATG and DCBT, and in these cases phenotypical114differences between the two cord blood units regarding memory
phenotype were found.GVH/GVL318
TARGETING OF HLA CLASS II RESTRICTED ANTIGENS IN GRAFT VERSUS
LEUKEMIA REACTIVITY
Falkenburg, J.H.F., Stumpf, A., Rutten, C.E., van der Meijden, E.D.,
Luxemburg-Heijs, S.A.P., van Bergen, C.A.M., Willemze, R.,
Griffioen, M. Leiden University Medical Center, Leiden, Netherlands
The beneficial effect of allogeneic HLA matched stem cell trans-
plantation (SCT) can be attributed to T cells recognizing minor histo-
compatibility antigens (mHag) expressed on hematopoietic cells of
recipient origin. T cells recognizing HLA class I restricted mHag se-
lectively expressed on hematopoietic cells have been shown to be capa-
ble of inducing Graft versus Leukemia/lymphoma (GVL) reactivity
without significant Graft versus Host Disease (GVHD). Since HLA
class II is predominantly expressed on hematopoietic cells, we charac-
terized the role of HLA class II directed T cell responses in GVL re-
activity. Since the HLA class II locus consists on HLA-DR, HLA-
DQ and HLA-DP we identified whether all different class II molecules
could be involved in GVL reactivity. First, we identified the role of
CD4 T cells in a patient successfully treated with donor lymphocyte in-
fusion (DLI) for relapsed leukemia after HLA matched SCT who
experienced only mild GVHD of the skin. 5 HLA class II restricted
mHag were molecularly identified including a HLA-DQ restricted
mHag were encoded by PI4K2B, and four HLA-DR restricted
mHag. These newly identified autosomal HLA-DR restricted mHag
were encoded by a NADP1dependentdehydrogenasegene (restricted
by DRB1*0301), a C-type lectin receptor gene (DRB1*1301), a protein
tyrosine kinase gene (DRB3*0101), and a non-classical MHC class I
gene (DRB3*0202). These genes show selective or predominant ex-
pression in cells of hematopoietic origin and the immunogenic variants
have balanced population frequencies of 25–70%. All T cell clones rec-
ognized high HLA class II-expressing patient-derived B-cells, mature
dendritic cells and in vitro cultured leukemic cells with antigen-pre-
senting phenotype. From a patient with a B cell leukemia successfully
treated with DLI resulting in GVL reactivity without GVHD we iden-
tified an exclusive T cell response targeting only HLA-DP expressed
on hematopoietic cells of recipient origen. We demonstrated that in
the absence of inflammatory cytokines none of the HLA class II re-
stricted T cells recognized non-hematopoietic cells. Only after pro-
found upregulation of HLA class II on non-hematopoietic cells,
some of the T cell clones could recognize non-hematopoietic tissues.
In conclusion, we demonstrate that HLA class II restricted alloreactive
T cells contribute to GVL reactivity in the absence of GVHD, and may
be sufficient to elicit anti-tumor reactivity in HLA class II expressing
hematological malignancies.319
PREVENTION OF ACUTE GVHD DURING HAPLO-BMT: EVALUATING THE
EFFICACY OF T-CELL COSTIMULATION BLOCKADE USING A NOVEL RHE-
SUS MACAQUE TRANSPLANT MODEL
Miller, W.P.1, Wheeler, C.E.1, Panoskaltsis-Mortari, A.2, Kirk, A.D.1,
Larsen, C.P.1, Blazar, B.R.2, Kean, L.S.1 1Emory University, Atlanta,
GA; 2University of Minnesota, Minneapolis, MN
We have developed a fully pedigreed and MHC-typed Rhesus ma-
caque BMT model, with which to study GvHD and its prevention.
For the current study, we have concentrated on MHC haplo-identi-
cal BMT, and determined the effect of T cell costimulation blockade
on GvHD prophylaxis. Our preparative regimen consists of TBI (8
Gy with lung shielding to 6 Gy). GvHD is graded using standard
clinical grading scales. Here we report on the first experimental co-
hort. The first animal served as a control for TBI-based preparation,
and, as expected exhibited profound pancytopenia. The second ani-
mal was transplanted with haploidentical hematopoietic stem cells
(4.47  108 total nucleated cells/kg and 1.10  108 CD31 T cells/
kg) and was treated with only rapamycin for immunosuppression.
He exhibited profuse diarrhea and necrotic skin changes within 8
days of transplant, coincident with early engraftment, and was sacri-
ficed at day 14. A diagnosis of Grade IV skin GvHD was rendered on
Poster Session-II 115the basis of significant epidermal hyperplasia, dyskeratosis, dermal fi-
brosis with hemorrhage, loss of hair follicles and sebaceious glands,
inflammation of subcutaneous fat tissue and hemorrhagic cysts.
These findings confirmed that GvHD could be induced using the
macaque model. The third animal was transplanted with haploident-
ical donor bone marrow (1.1 109 total nucleated cells/kg and 6.9
107 CD31 T cells/kg), but was given T cell costimulation blockade
with abatacept (targeting the CD28/B7 pathway) and an anti-CD40
antibody (targeting the CD40/CD154 pathway) in addition to rapa-
mycin. Abatacept is currently clinically approved for treatment of
rheumatoid arthritis, but has not been added to clinical GvHD reg-
imens, largely due to the paucity of translational efficacy data. This
animal maintained full donor chimerism (including 100% T and B
cell chimerism), until day 63 when he was sacrificed, without signs
of GvHD. Additional animals are now being added to the study, to
confirm these initial results.
Conclusions: 1. We have established a robust non-human pri-
mate model of GvHD using pedigreed and MHC-typed rhesus ma-
caques. 2. We have used this model to begin to test the efficacy of
a novel agent combination, capable of preventing the onset and com-
plications of acute GvHD. 3. Preliminary results suggest that CD28-
and CD40-directed costimulation blockade may be active agents for
the prevention of GvHD. A large scale analysis of their efficacy and
immune consequences is currently underway.320
EVALUATION OF OPTIMAL BLOOD CONCENTRATION OF TACROLIMUS
FOR THE PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM
UNRELATED DONOR
Mori, T., Aisa, Y., Kato, J., Nakamura, Y., Ikeda, Y., Okamoto, S. Keio
University School of Medicine, Tokyo, Japan
Background: Optimal blood concentration of tacrolimus for the
prophylaxis of GVHD after allogeneic hematopoietic stem cell
transplantation (HSCT) has not been established. Our retrospective
analysis has shown that incidence of Grades II-IV acute GVHD in
patients with mean tacrolimus concentration less than 15 ng/ml
was significantly higher than that in patients with mean tacrolimus
concentration 15 ng/ml or higher. The present study has set the tar-
get tacrolimus concentration between 15 and 20 ng/ml, and evalu-
ated the efficacy in preventing the development of acute GVHD
after allogeneic HSCT from unrelated donor.
Patients and Methods: Patients undergoing allogeneic HSCT
from an HLA-serologically matched unrelated donor for hemato-
logical diseases were evaluated. Stem cell source was bone marrow
in all patients. For the prophylaxis of GVHD, tacrolimus and meth-
otrexate were administered. Tacrolimus was given at an initial dose
of 0.03 mg/kg by continuous intravenous infusion from day -1, and
its dose was arranged to maintain its blood level at 15–20ng/ml dur-
ing the first 4 weeks after HSCT. MTX was given at a dose of 15 mg/
m2 on day 1, and 10 mg/m2 on days 3, 6, and 11.
Results: Of the 55 evaluated patients, 20 (36.4%) patients devel-
oped grade II, 2 patients (3.6%) developed grade III, and no patient
developed grade IV acute GVHD. In multivariate analysis, HLA al-
lele mismatch was an only identified risk factor for developing grades
II-IV acute GVHD, while blood concentration of tacrolimus was
not. No serious complications resulting in discontinuation of tacro-
limus were observed.
Conclusions:Tacrolimus combined with methotrexatecould effec-
tively prevent the development of severe acute GVHD after allogeneic
HSCT from unrelated donor by maintaining its blood concentration
between 15 and 20 ng/ml in the early post-transplant period.321
VISUALIZING THE FATE OF FOXP3 PROTEIN IN HUMAN T-CELLS
Magg, T., Albert, M.H. Dr. von Haunersches Kinderspital der Universi-
taet Muenchen, Munich, Germany
Foxp3 plays a pivotal role in the development and function of reg-
ulatory T cells (Treg) which represent a promising tool for trans-
plantation tolerance induction. In murine but not human T cells,
forced expression of Foxp3 converts naive T cells into functional
Tregs. This might in part be due to the fact that Foxp3 proteinexpression is difficult to track because endogenous Foxp3 is also ex-
pressed in activated human T-cells. We therefore intended to track
the fate of ectopically expressed Foxp3 protein in human CD41 cells
with the aim of defining why forced Foxp3 overexpression was not
sufficient for gaining regulatory function and to learn about the
physiological regulation of Foxp3 protein in human T cells. We
used a non-viral nucleofection protocol for transfection of human
CD41 cells with a dual-expression plasmid of a GFP-Foxp3 fusion
protein and a truncated low affinity nerve growth factor receptor
(LNGFR) to allow for positive selection of transfected cells. As ex-
pected we could demonstrate that purified, transiently Foxp3 trans-
fected cells only weakly suppressed proliferation of T cells. We
found that the ectopically expressed Foxp3 protein disappeared
more quickly than Foxp3 mRNA levels which remained at high levels
for up to 4 days. Also in stably transfected T cell lines GFP-Foxp3
mRNA but not the fusion protein was detectable. We hypothesized
that this might be due to posttranslational protein degradation or
posttranscriptionally decreased protein synthesis. We observed ap-
pearance of Foxp3 protein in stably transfected Jurkat cells treated
with the proteasome inhibitor bortezomib implying ubiquitinylation
as one mechanism of Foxp3 protein degradation. By fluorescent mi-
croscopy we could demonstrate that Foxp3 was relocated from the
nucleus to the cytoplasm within 24 hours after transfection. Using
a plasmid encoding for a Foxp3 protein double-tagged with N-ter-
minal GFP and C-terminal YFP we found that the GFP tagged frag-
ment was relocated to the cytoplasm and disappeared after 4 days,
while the YFP tagged fragment remained in the nucleus. Both a nu-
clear import and a nuclear export motif in the coding sequence of
Foxp3 could be identified. Our findings demonstrate that human
Foxp3 protein expression is subject to a regulatory pathway control-
ling subcellular distribution as well as protein stability. This experi-
mental setup should provide a basis for further conclusions about the
natural biology of this important determinator of Treg function.322
HIGH BAFF:B CELL RATIOS AND CIRCULATING ACTIVATED B CELLS IN
CHRONIC GVHD
Sarantopoulos, S.1, Stevenson, K.E.2, Kim, H.T.2, Cutler, C.S.1,
Bhuiya, N.S.1, Schowalter, M.1, Ho, V.T.1, Joseph, S.J.1, Antin, J.H.1,
Jerome, R.1 1Dana-Farber Cancer Institute, Boston, MA; 2Dana-Farber
Cancer Institute, Boston, MA
Although rituximab is an effective treatment for steroid refractory
chronic GVHD (cGVHD), the mechanisms underlying B cell in-
volvement in cGVHD have not been elucidated. Previous studies
have demonstrated that patients with active cGVHD have high levels
of BAFF, a pivotal B cell survival cytokine. We hypothesized that B
cell reconstitution in the context of high BAFF after HSCT could
support activated, potentially pathologic B cell populations that are
most dependent on BAFF for survival. We first performed detailed
phenotypic and functional analyses of peripheral B cells in 57 patients
.12 month post-HSCT and 33 healthy controls (see table).
BAFF:
Patient
Group
(median
month
post-HSCT)
(B Cell
Ratio
ng BAFF/
1000
B cells)p-value
vs. no
cGVHD (Median
Naive B
Cell
Number
1000/L) cp-value
vs. no
GVHD
T
Median
ransitional
B Number
(1000/L) cp-value
vs. no
GVHDHealthy
(no-HSCT)
n5330.008 0.48 89.5 0.0004 14.4 0.02No cGVHD
(27 mo.)
n5120.008 260.5 28.7Inactive
cGVHD
(31 mo.)
n5230.026 0.01 99.1 0.0005 8.5 0.04Active
cGVHD
(21 mo.)
n5220.046 \0.0001 79.8 0.0009 8.1 0.04
